ClinicalTrials.gg
CompletedNCT05096598Updated Jan 17, 2023

A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants

A Phase 1 interventional study of ZP8396 and Placebo (ZP8396) in Overweight and Healthy Volunteers, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-17.

Sponsored by Zealand Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies in Overweight with a site in Germany — 40 open to participants now, 62 under way, 34 of them phase 3. Overweight · Germany.

Enrollment
110th of 142
64 · median 131
Started
2021
with 5 others
Phase 1
25 of 151
7 open now
Registered
69th of 151
by date
Lead sponsor
6 of 151
Zealand Pharma

Among the 151 studies in Overweight with a site in Germany, this one is the 110th largest by enrollment of the 142 interventional ones that give a count, is one of 6 that started in 2021, is one of 25 in phase 1, and was the 69th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

40 of the 151 studies in Overweight with a site in Germany are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Overweight with a site in Germany, or all of them as a file.
02

Study summary

The research study will investigate the safety and tolerability of ZP8396 in healthy study participants. In addition, the study will investigate how ZP8396 works in the body (pharmacokinetics and pharmacodynamics).

Participants will receive 1 single dose either as an injection under the skin (subcutaneous, s.c.) or an injection into a vein of one arm (intravenous, i.v.).

Participants will have 9 visits with the study team. One of these visits consists of 8 overnight stays at the study site. For each participant, the study will last up to 66 days.

03

Conditions studied

  • Overweight
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subject
  • (BMI) between 21.0 and 29.9 kg/m\^2, both inclusive
  • Body weight of at least 70.0 kg
  • Glycosylated (HbA1c) less than 5.7 percent
  • Further inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • History of metabolic diseases more frequently associated with obesity, e.g. type-2-diabetes mellitus, hypertension, dyslipidemia, heart disease or stroke
  • Systolic blood pressure \< 90 mmHg or >139 mmHg and/or diastolic blood pressure less than 50 mmHg or greater than 89 mmHg
  • Symptoms of arterial hypotension
  • Further exclusion criteria apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    ZP8396

    Up to 10 single dose cohorts are planned with 8 subjects in each; 6 participants in each cohort will receive active treatment.

    Drug: ZP8396

  • Placebo comparator
    Placebo (ZP8396)

    In each of the 10 single dose cohorts, 2 subjects will receive placebo.

    Drug: Placebo (ZP8396)

Interventions

  • DrugZP8396

    Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.

  • DrugPlacebo (ZP8396)

    Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Time frame: From dosing (Day 1) to end of trial (Day 50)

Secondary outcomes

  1. Pharmacokinetics (PK) of ZP8396 (AUCτ)

    Area under the plasma concentration-time curve over a dosing interval

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  2. Pharmacokinetics (PK) of ZP8396 (AUCinf)

    Area under the plasma concentration-time curve from time zero to infinity

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  3. Pharmacokinetics (PK) of ZP8396 (AUClast)

    Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  4. Pharmacokinetics (PK) of ZP8396 (Cmax)

    Maximum (peak) plasma drug concentration

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  5. Pharmacokinetics (PK) of ZP8396 (tmax)

    Time to reach maximum (peak) plasma concentration

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  6. Pharmacokinetics (PK) of ZP8396 (λz)

    Elimination rate constant

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  7. Pharmacokinetics (PK) of ZP8396 (t½)

    Elimination half-life

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  8. Pharmacokinetics (PK) of ZP8396 (Vz/f)

    Apparent volume of distribution during terminal phase

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  9. Pharmacokinetics (PK) of ZP8396 (Vz)

    Volume of distribution during the terminal phase (i.v. only)

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  10. Pharmacokinetics (PK) of ZP8396 (CL/f)

    Apparent total clearance of the drug from plasma

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  11. Pharmacokinetics (PK) of ZP8396 (CL)

    Total body clearance of the drug (i.v. only)

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  12. Pharmacokinetics (PK) of ZP8396 (MRT)

    Mean residence time

    Time frame: Day 1 (pre-dose) to Day 50 (1176 hours post-dose)

  13. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (Cmax acetaminophen)

    Maximum acetaminophen concentration after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  14. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (Tmax acetaminophen)

    Time to maximum acetaminophen concentration after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  15. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (AUCacetaminophen, 0-60 min)

    Area under the acetaminophen concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  16. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (AUCacetaminophen, 0-240 min)

    Area under the acetaminophen concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  17. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (Cmax, Plasma Glucose [PG])

    Maximum PG concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  18. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (Tmax, Plasma Glucose [PG])

    Time to maximum PG concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  19. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (AUCPG,0-60 min)

    Area under the Plasma Glucose (PG) concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  20. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (AUCPG,0-240 min)

    Area under the Plasma Glucose (PG) concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  21. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (Cmax, insulin)

    Maximum insulin concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  22. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (Tmax, insulin)

    Time to maximum insulin concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  23. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (AUCinsulin,0-60 min)

    Area under the insulin concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  24. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (AUCinsulin,0-240 min)

    Area under the insulin concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  25. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (Cmax, glucagon)

    Maximum glucagon concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  26. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (Tmax, glucagon)

    Time to maximum glucagon concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  27. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (AUCglucagon,0-60 min)

    Area under the glucagon concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

  28. Pharmacodynamics (PD) of ZP8396, for dose cohorts greater than or equal to 0.7 mg (AUCglucagon,0-240 min)

    Area under the glucagon concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 and Day 5

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, North Rhine-Westphalia 41460, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jan 2023, 14 months.

Of 212 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 14 months is above that.

Counting every sponsor, half of 231 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2021
First posted
Oct 27, 2021
StartActual
Oct 19, 2021
Primary completionActual
Jan 12, 2023
CompletionActual
Jan 12, 2023
Last update
Jan 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05096598
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Oct 27, 2021
Start date
Oct 19, 2021
Primary completion
Jan 12, 2023
Completion
Jan 12, 2023
Last update
Jan 17, 2023

Study contacts

Zealand Pharma A/S
study director · Zealand Pharma A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Petrelintide

Start the discussion